{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T17:49:21Z","timestamp":1785347361987,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Combining lipid-lowering agents may enhance outcomes in patients with high-risk coronary artery disease. While rosuvastatin is known to reduce LDL-C and cardiovascular events, the additional benefit of ezetimibe remains under investigation. This meta-analysis evaluated the efficacy and safety of RSV combined with EZ compared to RSV monotherapy in high-risk coronary artery disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A systematic review was conducted using PubMed, Scopus, and Google Scholar up to August 30, 2024. Data were analyzed using a random-effects model in Review Manager 5.4.\u00a0Lipid profile and safety outcomes were assessed in accordance with PRISMA guidelines. <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Combination therapy with rosuvastatin and ezetimibe significantly improved the lipid profile in high-risk coronary artery disease patients compared to rosuvastatin monotherapy, based on 11 studies with 1,963 subjects.\u00a0Treatment with RSV plus EZ\u00a0decreased total cholesterol by 0.50 units (SMD = -0.50; 95% CI: -0.80 to -0.19; p = 0.001), LDL-C by 0.57 units (SMD = -0.57; 95% CI: -0.80 to -0.33; p &lt; 0.00001), and triglycerides by 0.85 units (SMD = -0.85; 95% CI: -1.81 to -0.11; p = 0.002). Meanwhile, HDL-C increased by 0.26 units (SMD = 0.26; 95% CI: 0.04 to 0.48; p = 0.02). RSV monotherapy showed a significant risk of elevated liver enzymes (RR 0.36; 95% CI 0.13\u20130.99; <jats:italic>p<\/jats:italic>\u2009=\u20090.05), while combination therapy increased the risk of myalgia (RR 2.17; 95% CI 1.04\u20134.54; <jats:italic>p<\/jats:italic>\u2009=\u20090.04) and gastrointestinal symptoms (RR 2.00; 95% CI 1.01\u20133.97; <jats:italic>p<\/jats:italic>\u2009=\u20090.05). No significant difference in angina pectoris was noted (RR 0.84; 95% CI: 0.39\u20131.80; <jats:italic>p<\/jats:italic>\u2009=\u20090.65). <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Combination therapy with RSV and EZ effectively improves lipid profiles in high-risk coronary artery disease patients, particularly in reducing total cholesterol, LDL-C, and triglycerides. However, it is associated with a higher risk of gastrointestinal symptoms and myalgia. In contrast, RSV monotherapy is linked to a greater risk of elevated liver enzymes but was also associated with increased HDL-C compared to the combination therapy of RSV\u2009+\u2009EZ.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s43044-025-00654-y","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T08:48:51Z","timestamp":1749545331000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lipid profile and safety of rosuvastatin monotherapy versus rosuvastatin plus ezetimibe in high risk coronary artery disease: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"77","author":[{"given":"Arga","family":"Setyo Adji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atiyatum","family":"Billah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angga","family":"Nugraha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliardi Eka","family":"Putra Sit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Gervais de Liyis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdillah","family":"Maulana Satrio Aji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragil","family":"Nur Rosyid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bambang","family":"Edi Suwito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"issue":"5","key":"654_CR1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.amjcard.2006.10.022","volume":"99","author":"CM Ballantyne","year":"2007","unstructured":"Ballantyne CM, Weiss R, Moccetti T et al (2007) Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 99(5):673\u2013680. https:\/\/doi.org\/10.1016\/j.amjcard.2006.10.022","journal-title":"Am J Cardiol"},{"issue":"5","key":"654_CR2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.hlc.2015.10.012","volume":"25","author":"X Wang","year":"2016","unstructured":"Wang X, Zhao X, Li L, Yao H, Jiang Y, Zhang JY (2016) Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart Lung Circ 25(5):459\u2013465","journal-title":"Heart Lung Circ"},{"key":"654_CR3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1536\/ihj.14-311","volume":"56","author":"J Masuda","year":"2015","unstructured":"Masuda J, Tanigawa T, Yamada T et al (2015) Effect of Combination Therapy of Ezetimibe and Rosuvastatin on Regression of Coronary Atherosclerosis in Patients With coronary artery disease. Int Heart J 56:278\u2013285","journal-title":"Int Heart J"},{"key":"654_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijcard.2017.02.099","volume":"235","author":"D Ran","year":"2017","unstructured":"Ran D, Nie H, juan, Gao Y lin, et al (2017) A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin. Int J Cardiol 235:49\u201355. https:\/\/doi.org\/10.1016\/j.ijcard.2017.02.099","journal-title":"Int J Cardiol"},{"key":"654_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/2995602","volume":"2021","author":"C Sun","year":"2021","unstructured":"Sun C, Zheng W, Liang L, Liu Z, Sun W, Tang R (2021) Ezetimibe improves rosuvastatin effects on inflammation and vascular endothelial function in acute coronary syndrome patients undergoing PCI. J Interv Cardiol 2021:1\u20137. https:\/\/doi.org\/10.1155\/2021\/2995602","journal-title":"J Interv Cardiol"},{"key":"654_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030414","author":"J Lewek","year":"2023","unstructured":"Lewek J, Niedziela JT, Desperak P et al (2023) Intensive statin therapy versus upfront combination therapy of statin and ezetimibe in patients with acute coronary syndrome: a propensity score matching analysis based on the PL-ACS Data. J Am Heart Assoc Cardiovasc and Cerebrovasc Disease. https:\/\/doi.org\/10.1161\/JAHA.123.030414","journal-title":"J Am Heart Assoc Cardiovasc and Cerebrovasc Disease"},{"issue":"1","key":"654_CR7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.clinthera.2016.11.014","volume":"39","author":"YJ Yang","year":"2017","unstructured":"Yang YJ, Lee SH, Kim BS et al (2017) Combination therapy of rosuvastatin and ezetimibe in patients with high cardiovascular risk. Clin Ther 39(1):107\u2013117","journal-title":"Clin Ther"},{"key":"654_CR8","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s13300-020-00778-1","volume":"11","author":"J Lee","year":"2020","unstructured":"Lee J, Hwang YC, Lee WJ et al (2020) Comparison of the efficacy and safety of rosuvastatin\/ezetimibe combination therapy and rosuvastatin monotherapy on lipoprotein in patients with type 2 diabetes: multicenter randomized controlled study. Diabetes Therapy 11:859\u2013871","journal-title":"Diabetes Therapy"},{"key":"654_CR9","first-page":"57","volume":"41","author":"Y Wu","year":"2014","unstructured":"Wu Y, Chen K, Yang SY, Fu X, Ming JZ (2014) Effects of the combination of ezetimibe and rosuvastatin on coronary atherosclerotic plaque. Central Plains Med J 41:57\u201359","journal-title":"Central Plains Med J"},{"issue":"25","key":"654_CR10","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP et al (2015) Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372(25):2387\u20132397","journal-title":"N Engl J Med"},{"issue":"4","key":"654_CR11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jacl.2007.07.003","volume":"1","author":"EA Stein","year":"2007","unstructured":"Stein EA, Ose L, Retterst\u00f8l K et al (2007) Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia. J Clin Lipidol 1(4):280\u2013286","journal-title":"J Clin Lipidol"},{"key":"654_CR12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijcard.2015.04.121","volume":"190","author":"SH Chang","year":"2015","unstructured":"Chang SH, Wu LS, Lee CH et al (2015) Simvastatin-ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: A population-based dynamic cohort study. Int J Cardiol 190:20\u201325","journal-title":"Int J Cardiol"},{"issue":"8","key":"654_CR13","first-page":"703","volume":"11","author":"E Namal","year":"2011","unstructured":"Namal E, Sener N, Ula\u015f T, Ak\u00e7al\u0131 Z, Oztekin E, Borlu F (2011) Effects of different statins, ezetimibe\/simvastatin combination on hsCRP levels in unstable angina pectoris and non-ST elevation myocardial infarction patients: a randomized trial. Anadolu Kardiyol Derg 11(8):703\u2013710","journal-title":"Anadolu Kardiyol Derg"},{"issue":"4","key":"654_CR14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ancard.2014.04.018","volume":"63","author":"P Deharo","year":"2014","unstructured":"Deharo P, Pankert M, Quilici J et al (2014) Safety and effectiveness of the association ezetimibe-statin (E-S) versus high dose rosuvastatin after acute coronary syndrome: the SAFE-ES study. Ann Cardiol Angeiol (Paris) 63(4):222\u2013227","journal-title":"Ann Cardiol Angeiol (Paris)"},{"issue":"2","key":"654_CR15","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.clinthera.2017.12.018","volume":"40","author":"SJ Hong","year":"2018","unstructured":"Hong SJ, Jeong HS, Ahn JC, Phase A III et al (2018) Multicenter, randomized, double-blind, active comparator clinical trial to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus rosuvastatin monotherapy in patients with hypercholesterolemia: I-ROSETTE (ildong rosuvastatin & ezetimibe for hyperch. Clin Ther 40(2):226\u2013241","journal-title":"Clin Ther"},{"issue":"5","key":"654_CR16","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ahj.2008.07.023","volume":"156","author":"CP Cannon","year":"2008","unstructured":"Cannon CP, Giugliano RP, Blazing MA et al (2008) Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 156(5):826\u2013832","journal-title":"Am Heart J"},{"key":"654_CR17","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/bmj.n71","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2020) The PRISMA statement: An updated guideline for reporting systematic reviews. The BMJ 2021:372. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"The BMJ"},{"key":"654_CR18","unstructured":"The Cochrane Collaboration., Review manager (RevMan) Version 5.4. 2020. Accessed April 13, 2024. https:\/\/training.cochrane.org\/System\/Files\/Uploads\/Protected_file\/RevMan5.4_user_guide.Pdf"},{"key":"654_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10122594","author":"M Setny","year":"2021","unstructured":"Setny M, Jankowski P, Krzykwa A et al (2021) Management of dyslipidemia in women and men with coronary heart disease: results from polaspire study. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10122594","journal-title":"J Clin Med"},{"key":"654_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1925539","author":"V Barrios","year":"2021","unstructured":"Barrios V, Escobar C (2021) Fixed-dose combination of rosuvastatin and ezetimibe: treating hypercholesteremia according to cardiovascular risk. Expert Rev Clin Pharmacol. https:\/\/doi.org\/10.1080\/17512433.2021.1925539","journal-title":"Expert Rev Clin Pharmacol"},{"key":"654_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/1476-511X-12-9","author":"D Yamazaki","year":"2013","unstructured":"Yamazaki D, Ishida M, Watanabe H et al (2013) Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe. Lipids Health Dis. https:\/\/doi.org\/10.1186\/1476-511X-12-9","journal-title":"Lipids Health Dis"},{"key":"654_CR22","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S332352","author":"MR Chilbert","year":"2022","unstructured":"Chilbert MR, Vanduyn D, Salah S, Clark CM, Ma Q (2022) Combination therapy of ezetimibe and rosuvastatin for dyslipidemia: current insights. Drug Des Devel Ther. https:\/\/doi.org\/10.2147\/DDDT.S332352","journal-title":"Drug Des Devel Ther"},{"key":"654_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13071894","author":"JM Mostaza","year":"2024","unstructured":"Mostaza JM, Escobar C (2024) Rosuvastatin-based lipid-lowering therapy for the control of LDL cholesterol in patients at high vascular risk. J Clin Med. https:\/\/doi.org\/10.3390\/jcm13071894","journal-title":"J Clin Med"},{"key":"654_CR24","doi-asserted-by":"publisher","DOI":"10.4137\/CMC.S4324","author":"A Luvai","year":"2012","unstructured":"Luvai A, Mbagaya W, Hall AS, Barth JH (2012) Rosuvastatin: A review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol. https:\/\/doi.org\/10.4137\/CMC.S4324","journal-title":"Clin Med Insights Cardiol"},{"issue":"10","key":"654_CR25","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/S0002-9149(02)02774-1","volume":"90","author":"C Gagn\u00e9","year":"2002","unstructured":"Gagn\u00e9 C, Bays HE, Weiss SR et al (2002) Efficacy and safety of <em>ezetimibe<\/em> added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 90(10):1084\u20131091. https:\/\/doi.org\/10.1016\/S0002-9149(02)02774-1","journal-title":"Am J Cardiol"},{"issue":"1","key":"654_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3349\/ymj.2023.0285","volume":"65","author":"Y Kang","year":"2024","unstructured":"Kang Y, Park JM, Lee SH (2024) Moderate-intensity rosuvastatin\/ezetimibe combination versus quadruple-dose rosuvastatin monotherapy: a meta-analysis and systemic review. Yonsei Med J 65(1):19\u201326. https:\/\/doi.org\/10.3349\/ymj.2023.0285","journal-title":"Yonsei Med J"},{"issue":"12","key":"654_CR27","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1016\/j.clinthera.2019.10.010","volume":"41","author":"MY Rhee","year":"2019","unstructured":"Rhee MY, Kim KJ, Kim SH et al (2019) Ezetimibe and rosuvastatin combination treatment can reduce the dose of rosuvastatin without compromising its lipid-lowering efficacy. Clin Ther 41(12):2571\u20132592. https:\/\/doi.org\/10.1016\/j.clinthera.2019.10.010","journal-title":"Clin Ther"},{"issue":"6","key":"654_CR28","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.clinthera.2018.04.015","volume":"40","author":"W Kim","year":"2018","unstructured":"Kim W, Yoon YE, Shin SH et al (2018) Efficacy and safety of ezetimibe and rosuvastatin combination therapy versus those of rosuvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 40(6):993\u20131013. https:\/\/doi.org\/10.1016\/j.clinthera.2018.04.015","journal-title":"Clin Ther"},{"key":"654_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043714","author":"JW Davis","year":"2021","unstructured":"Davis JW, Weller SC (2021) Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients. BMJ Open. https:\/\/doi.org\/10.1136\/bmjopen-2020-043714","journal-title":"BMJ Open"},{"key":"654_CR30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00392-018-1379-z","volume":"108","author":"M Lorenzi","year":"2018","unstructured":"Lorenzi M, Ambegaonkar B, Baxter C, Jansen J, Zoratti M, Davies G (2018) Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy. Clin Res Cardiol 108:487\u2013509. https:\/\/doi.org\/10.1007\/s00392-018-1379-z","journal-title":"Clin Res Cardiol"},{"key":"654_CR31","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1177\/1479164111418136","volume":"8","author":"M Averna","year":"2011","unstructured":"Averna M, Missault L, Vaverkova H et al (2011) Lipid-altering efficacy of switching to ezetimibe\/simvastatin 10\/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome. Diab Vasc Dis Res 8:262\u2013270. https:\/\/doi.org\/10.1177\/1479164111418136","journal-title":"Diab Vasc Dis Res"},{"key":"654_CR32","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.61526","author":"S Dadzie","year":"2024","unstructured":"Dadzie S, Tabowei G, Kaur M et al (2024) A comparison of rosuvastatin monotherapy and rosuvastatin plus ezetimibe combination therapy in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Cureus. https:\/\/doi.org\/10.7759\/cureus.61526","journal-title":"Cureus"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-025-00654-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-025-00654-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-025-00654-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T08:48:54Z","timestamp":1749545334000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-025-00654-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["654"],"URL":"https:\/\/doi.org\/10.1186\/s43044-025-00654-y","relation":{},"ISSN":["2090-911X"],"issn-type":[{"value":"2090-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}